Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol

Sun, Xiao; Zhang, Man; Sanagawa, Akimasa; Mori, Chieko; Ito, Shiori; Iwaki, Soichiro; Satoh, Hiroki; Fujii, Satoshi

doi:10.1186/1477-9560-10-16

Cited by 89 publications

(78 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[17][18][19] However, the use of plasma miRNAs in gene expression studies faces technical limitations because of the extremely low concentrations of miRNAs freely circulating in plasma. Also, the absence of ribosomal RNAs in these samples makes the assessment of the RNA quality difficult.…”

Section: Stather Et Al Mirnas In Pad 491mentioning

confidence: 99%

Differential MicroRNA Expression Profiles in Peripheral Arterial Disease

Stather

Sylvius

Wild

et al. 2013

Circ Cardiovasc Genet

View full text Add to dashboard Cite

Background— Peripheral arterial disease (PAD) is a clinical condition caused by an atherosclerotic process affecting the arteries of the limbs. Despite major improvements in surgical endovascular techniques, PAD is still associated with high mortality and morbidity. Recently, microRNAs (miRNAs), a class of short noncoding RNA controlling gene expression, have emerged as major regulators of multiple biological processes. Methods and Results— A whole-miRNA transcriptome profiling was performed in peripheral blood from an initial sample set of patients and controls. A 12-miRNA PAD-specific signature, which includes let 7e, miR-15b, -16, -20b, -25, -26b, -27b, -28-5p, -126, -195, -335, and -363, was further investigated and validated in 2 additional sample sets. Each of these 12 miRNAs exhibited good diagnostic value as evidenced by receiver operating characteristic curve analyses. Pathway enrichment analysis using predicted and validated targets identified several signaling pathways relevant to vascular disorders. Several of these pathways, including cell adhesion molecules, were confirmed by quantifying the expression level of several candidate genes regulating the initial stages of the inflammatory atherosclerotic process. The expression level of 7 of these candidate genes exhibits striking inverse correlation with that of several, if not all, of the miRNAs of the PAD-specific miRNA signature. Conclusions— These results demonstrate the potential of miRNAs for the diagnosis of PAD and provide further insight into the molecular mechanisms leading to the development of PAD, with the potential for future therapeutic targets.

show abstract

Section: Stather Et Al Mirnas In Pad 491mentioning

confidence: 99%

Differential MicroRNA Expression Profiles in Peripheral Arterial Disease

Stather

Sylvius

Wild

et al. 2013

Circ Cardiovasc Genet

View full text Add to dashboard Cite

show abstract

“…In particular, aberrant expression of miRNA-126 was found in patients with atrial fibrillation, heart failure and CAD 10,11 , suggesting a regulatory role of miRNA-126 in cardiovascular system. Therefore, we first investigated the role of miR-126 in atherosclerosis/CAD in this study.…”

mentioning

confidence: 99%

Expression of miR-126 and its potential function in coronary artery disease

et al. 2017

View full text Add to dashboard Cite

Objective: This study aimed to explore the role of miR-126 in coronary artery disease (CAD) patients and the potential gene targets of miR-126 in atherosclerosis. Methodology: A total of 60 CAD patients and 25 healthy control subjects were recruited in this study. Among the 60 CAD patients, 18 cases were diagnosed of stable angina pectoris (SAP), 20 were diagnosed of unstable angina pectoris (UAP) and 22 were diagnosed of acute myocardial infarction (AMI). Plasma miR-126 levels from both groups of participants were analyzed by real-time quantitative PCR. ELISA was used to measure plasma level of placenta growth factor (PLGF). Results:The results showed that the miR-126 expression was significantly down-regulated in the circulation of CAD patients compared with control subjects (P<0.01). Plasma PLGF level was significantly upregulated in patients with unstable angina pectoris and acute myocardial infarction (AMI) compared with controls (both P<0.01) the miR-126 expression in AMI was significantly associated with PLGF. Conclusion: miR-126 may serve as a novel biomarker for CAD.

show abstract

“…miR-33 an intronic miRNA is first reported with transcription regulator of sterol regulator binding gene SRBP2 involved in cholesterol metabolism (Rayner et al, 2010). Moreover, several other miRNAs including miR-92a (Loyer et al, 2014), miR-146a/b (Takahashi et al, 2010), miR-195 (Latranico et al, 2009, have been reported to have important regulatory roles in cardiovascular diseases. There are several miRNAs reported to have association with myocardial infarction (MI) like miR-126 associated with diabetes (Zampetaki et al, 2010), hyperlipodemia and age (Fukushima et al, 2011) the high levels of presence makes the patients with 2.7 fold higher risks of MI.…”

Section: Sumoylation and Inflammatory Pathwaymentioning

confidence: 99%

SUMOylation: A link to future therapeutics

2016

Current Issues in Molecular Biology

View full text Add to dashboard Cite

SUMOylation, much of a similar process like ubiquitination catches attention across various research groups as a potential therapeutic target to fight various infectious and cancerous diseases. This idea take its strength from recent reports which unearth the molecular mechanisms of SUMOylation and its involvement in important diseases distributed across various kingdoms. At the beginning SUMOylation was considered a process affected only by viral diseases but subsequent reports enlighten its role in diseases caused by bacteria as well. This enhances the SUMOylation canvas and demanded more in-depth study of the process. The present review is an attempt to study the regulatory mechanism of genes when the natural SUMOylation pathway is disturbed, the cross-talk among SUMOylation and other post translational modifications, the role of miRNAs in controlling the function of transcripts, loading of RNA species into exosomes and the possible SUMOylation related therapeutic targets. IntroductionThe innate immune responses across kingdoms are tightly regulated to fight attacking pathogens. Post translational modification of proteins like acetylation, methylation, ubiquitination and SUMOylation have predominant role in activation/deactivation of immune responses by regulating various cellular processes including transcription, DNA repair, proliferation and apoptosis as these have the potential to relocate the protein to different organelles and modify its biological function. The deep understanding of those post translational mechanisms could provide insights in controlling several disease conditions and develop therapeutics based on those post translational modification markers.The small ubiquitin like modifiers (SUMO) proteins discovered in 1997 (Mahajan et al., 1997) has since been recognized as family of important modification proteins unlike ubiquitination which is involved in degradation of proteins, instead it modulates the function of target proteins. The covalent conjugation of SUMO molecules to protein residue lysine on a typical consensus sequence ψKxD/E (where ψ is large hydrophobic residue, K is the target lysine, D/E is acidic residue and x represent any amino acid) (Rodriguez et al., 2001;Sampson et al., 2001). The process of SUMOylation is carried out by a cascade of three enzymes (E1, E2 and E3). E1 is a SUMO activating enzyme SAE1, while E2 is conjugating enzyme e.g. Ubc9 and E3 is SUMO ligase. The SUMOylation reaction is reversed by SENPs termed as deSUMOylation having distinct regulatory roles. Till date four SUMO molecules have been reported in mammals viz., SUMO1, SUMO2, SUMO3 and SUMO4. The sequence similarity of SUMO2 and SUMO3 are almost 97% hence are often reported collectively as SUMO2/3. Various kinds of stimuli like oxidative stress often increase the rate of SUMOylation. A recent report shows the exposure to cigarette smoke alters the microRNA expression by SUMOylation of DICER (Gross et al., 2014). Viruses and chemical toxins also causes an increase in SUMOylation, a well known exam...

show abstract

Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol

Cited by 89 publications

References 20 publications

Differential MicroRNA Expression Profiles in Peripheral Arterial Disease

Differential MicroRNA Expression Profiles in Peripheral Arterial Disease

Expression of miR-126 and its potential function in coronary artery disease

SUMOylation: A link to future therapeutics

Contact Info

Product

Resources

About